1-4 of 4
Shringi Sharma, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Exposure-Response of Entospletinib (ENTO) for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia

Sneha Gupta, PhD, Amy Meng, PhD, Shringi Sharma, PhD, Wei Ye, PhD, Jeffrey Silverman, PhD, Esteban M. Abella, MD, Anita Mathias, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1735.
https://doi.org/10.1182/blood.V130.Suppl_1.1735.1735
Published: 2017
Journal Articles

Exposure-Response of Idelalisib Administered in Combination with Bendamustine and Rituximab for the Treatment of Relapsed Chronic Lymphocytic Leukemi

Vinay Manu Daryani, PharmD, Shringi Sharma, PhD, Guan Xing, PhD, Jeffrey Silverman, PhD, Adeboye Henry Adewoye, MD, Anita Mathias, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 5344.
https://doi.org/10.1182/blood.V130.Suppl_1.5344.5344
Published: 2017
Journal Articles

Phase 1b and Pharmacokinetic Study of Idelalisib in Japanese Patients with Relapsed or Refractory (R/R) Indolent B-Cell Non-Hodgkin Lymphoma (iNHL) or Chronic Lymphocytic Leukemia (CLL)

Tomohiro Kinoshita, MD PhD, Noriko Fukuhara, MD PhD, Hirokazu Nagai, MD PhD, Koji Izutsu, MD, Yukio Kobayashi, MD PhD, Yusuke Higuchi, MD, Hideo Harigae, MD, Takashi Tokunaga, MD PhD, Henry Adewoye, MD, Michelle Robeson, ND, Shringi Sharma, PhD, Masato Fukui, MD, Jie Gao, PhD, Christine Christenson, Kensei Tobinai, MD PhD
Journal: Blood
Blood (2015) 126 (23): 5089.
https://doi.org/10.1182/blood.V126.23.5089.5089
Published: 2015
Journal Articles

Exposure-Response of Idelalisib Administered in Combination with Ofatumumab for the Treatment of Relapsed Chronic Lymphocytic Leukemia

Shringi Sharma, PhD, Ying Guo, PhD, Feng Jin, PhD, Xiaoming Li, PhD, Ronald L. Dubowy, MD, Terry Newcomb, PhD, Srini Ramanathan, PhD
Journal: Blood
Blood (2015) 126 (23): 4172.
https://doi.org/10.1182/blood.V126.23.4172.4172
Published: 2015